Alexandrite Candela Laser as the Modern Gold Standard for Laser Hair Removal: A Review of Clinical Evidence (2024–2025)

Over the past decade, laser hair removal has undergone significant technological advancement, with the 755 nm alexandrite laser remaining one of the most extensively studied and clinically validated technologies for long-term hair reduction. Owing to its high melanin selectivity and optimal depth of penetration, this wavelength consistently delivers excellent clinical outcomes while maintaining a low risk of adverse effects.

Particular attention has been given to laser systems developed by Candela. Devices such as the GentleLase Pro and GentleMax Pro Plus have been widely used in international clinical research for many years and are regarded as technological benchmarks in laser hair removal.

Recent publications from 2024–2025 further reinforce the effectiveness, safety, and therapeutic potential of the alexandrite laser—not only in aesthetic dermatology but also in the management of several clinical conditions associated with hypertrichosis and chronic inflammation. The following review summarizes the most relevant clinical studies and scientific publications reflecting the current evidence base for this technology.

Clinical Evidence and Safety

One of the most significant recent studies was published in 2025 and indexed in PubMed (PMID: 40557173). The study evaluated the safety of alexandrite laser hair removal in patients with systemic lupus erythematosus (SLE). Twenty participants underwent treatment over a six-month period with sessions performed every 4–6 weeks. Disease activity was monitored using the SLEDAI-2K index, together with serum complement levels (C3 and C4) and anti-double-stranded DNA (anti-dsDNA) antibodies. None of these parameters demonstrated any clinically significant deterioration throughout the study.

These findings are particularly important because they support the safety of laser hair removal even in a patient population traditionally considered at increased risk from light-based therapies. When appropriate treatment parameters are used in combination with advanced epidermal cooling technologies—such as Candela’s Dynamic Cooling Device (DCD™)—alexandrite laser treatment appears to be safe even for patients with underlying autoimmune diseases.

Another comprehensive review published on ResearchGate in 2024, entitled “Alexandrite Laser for Hair Reduction: Updates and What Is New,” analyzed data from more than 30 clinical studies conducted during the previous five years. The authors reported an average long-term hair density reduction of 70–90% after 6–8 treatment sessions performed at six-week intervals. In most patients, clinical improvement remained stable for up to 24 months when annual maintenance treatments were performed.

The review also concluded that the 755 nm alexandrite laser offers the highest balance of efficacy and safety for Fitzpatrick skin phototypes I–III. For patients with darker skin (phototypes IV–V), combined laser platforms or 1064 nm Nd lasers are generally preferred to minimize the risk of post-inflammatory hyperpigmentation.

Emerging Therapeutic Applications

The therapeutic potential of the alexandrite laser has recently expanded beyond cosmetic indications. A 2024 study published on ScienceDirect investigated its use in the treatment of hidradenitis suppurativa, a chronic inflammatory disorder affecting hair follicles.

Following 4–6 treatment sessions with a 755 nm alexandrite laser, patients demonstrated a significant reduction in inflammatory activity, pain severity, and disease recurrence. These benefits are believed to result from selective destruction of hair follicles together with a reduction in bacterial colonization.

The findings suggest that alexandrite laser technology may play an increasingly important role not only in aesthetic medicine but also in therapeutic dermatology.

Clinical Performance of Candela GentleMax Pro and GentleMax Pro Plus

Key clinical data regarding the Candela GentleMax Pro and GentleMax Pro Plus platforms are available through ClinicalTrials.gov (Identifier: NCT04975243). This ongoing clinical trial evaluates the safety and effectiveness of the dual-wavelength system combining 755 nm alexandrite and 1064 nm Nd lasers for the treatment of unwanted fine facial hair in patients across Fitzpatrick skin phototypes I–VI.

Interim results demonstrate excellent treatment tolerability, high clinical efficacy, and no serious treatment-related adverse events.

In 2023, The PMFA Journal published a comparative study evaluating two pulse durations (2 ms versus 3 ms) using the GentleMax Pro Plus alexandrite laser. After two treatment sessions, hair density was reduced by approximately 50% with the 2 ms pulse duration compared with 45% using the 3 ms setting. Five months later, reductions remained at 38% and 29%, respectively. No participant developed burns or persistent pigmentary changes. The authors concluded that shorter pulse durations may provide a modest improvement in treatment efficacy while maintaining an excellent safety profile.

Advantages of Dual-Wavelength Systems

A 2023 multicenter study published on ResearchGate involving more than 2,000 patients with various skin phototypes demonstrated that combining the 755 nm alexandrite laser with the 1064 nm Nd laser resulted in hair reduction rates of 60–90%, while maintaining a very low complication rate (<2%).

The ability to individualize treatment parameters—including fluence, pulse duration, and cooling settings—allows clinicians to safely treat patients across virtually all Fitzpatrick skin types.

Limitations and Factors Influencing Treatment Outcomes

No currently available laser hair removal technology can permanently eliminate every hair follicle. Partial hair regrowth may occur over time due to hormonal influences, genetic predisposition, or activation of previously dormant follicles.

The recommended treatment protocol consists of 6–10 sessions performed at intervals of 6–8 weeks, followed by maintenance treatments once or twice annually. Optimal clinical outcomes require individualized parameter selection based on skin phototype, hair thickness, pigmentation, and photosensitivity.

Clinical Significance and Conclusions

The accumulated clinical evidence published between 2023 and 2025 supports Candela GentleLase, GentleMax Pro, and GentleMax Pro Plus systems as among the most scientifically validated and technologically advanced platforms currently available for laser hair removal.

Their clinical performance is largely attributable to the optimal 755 nm alexandrite wavelength, short pulse durations (2–3 ms), and Candela’s proprietary Dynamic Cooling Device (DCD™), which enhances both patient comfort and treatment safety.

For skin phototypes I–III, the alexandrite laser continues to represent the gold standard for laser hair removal. For darker skin types, combining the alexandrite wavelength with Nd technology offers greater safety while preserving high treatment efficacy.

Overall, the latest scientific evidence confirms that Candela laser technologies are supported by a robust clinical evidence base and continue to establish professional standards in modern laser hair removal.

References

1. Efficacy and Safety of Alexandrite Laser Epilation in Patients with Systemic Lupus Erythematosus. PubMed. PMID: 40557173; 2025.
2. Khattar JA, et al. Alexandrite Laser for Hair Reduction: Updates and What Is New. ResearchGate; 2024.
3. Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro™ / GentleMax Pro Plus™ 755 nm and 1064 nm Laser System for Unwanted Fine Facial Hair (NCT04975243). ClinicalTrials.gov; 2024.
4. Evaluating the Efficacy of 2-Millisecond versus 3-Millisecond Pulse Duration in Laser Hair Removal Using a 755 nm Alexandrite Laser (GentleMax Pro Plus). The PMFA Journal. September 2023.
5. Efficacy and Safety of Alexandrite and Nd Laser Combination in Permanent Hair Removal. ResearchGate. 2023.
6. Alexandrite Laser Treatment for Hidradenitis Suppurativa: A Therapeutic Option Beyond Cosmetic Use. ScienceDirect. 2024.
7. Candela Medical. Clinical Papers and Resources. 2025.
8. Anderson RR, Parrish JA. Selective Photothermolysis: Precise Microsurgery by Selective Absorption of Pulsed Radiation. Science. 1983;220(4596):524–527.